<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-04-29T00:37:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10242610" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10242610</identifier>
        <datestamp>2023-06-07</datestamp>
        <setSpec>phenaturepg</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Oral Investig</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Oral Investig</journal-id>
              <journal-title-group>
                <journal-title>Clinical Oral Investigations</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1432-6981</issn>
              <issn pub-type="epub">1436-3771</issn>
              <publisher>
                <publisher-name>Springer Berlin Heidelberg</publisher-name>
                <publisher-loc>Berlin/Heidelberg</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10242610</article-id>
              <article-id pub-id-type="pmcid">PMC10242610</article-id>
              <article-id pub-id-type="pmc-uid">10242610</article-id>
              <article-id pub-id-type="pmid">37278917</article-id>
              <article-id pub-id-type="pmid">37278917</article-id>
              <article-id pub-id-type="publisher-id">5051</article-id>
              <article-id pub-id-type="doi">10.1007/s00784-023-05051-w</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Significant efficacy of short-course, low-concentration betamethasone mouthwash therapy for severe erosive oral lichen planus: a randomized controlled trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Zeng</surname>
                    <given-names>Qingxiang</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Yangfan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Shimeng</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Houshang</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yu</surname>
                    <given-names>Shuang</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Fanglong</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Yang</surname>
                    <given-names>Jin</given-names>
                  </name>
                  <address>
                    <email>yangjin@scu.edu.cn</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Zhou</surname>
                    <given-names>Hongmei</given-names>
                  </name>
                  <address>
                    <email>zhouhm@scu.edu.cn</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Department of Oral Medicine, State Key Laboratory of Oral Diseases, National Center of Stomatology, National Clinical Research Center for Oral Diseases, Frontier Innovation Center for Dental Medicine Plus, West China Hospital of Stomatology, </institution><institution>Sichuan University, </institution></institution-wrap>No. 14, Sec. 3, Renmin South Road, Chengdu, 610041 Sichuan China </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>6</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <fpage>1</fpage>
              <lpage>12</lpage>
              <history>
                <date date-type="received">
                  <day>9</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>29</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</copyright-statement>
                <license>
                  <license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Objectives</title>
                  <p id="Par1">To evaluate the short-term efficacy of low-concentration betamethasone mouthwash for severe erosive oral lichen planus (EOLP).</p>
                </sec>
                <sec>
                  <title>Materials and method</title>
                  <p id="Par2">In this randomized, investigator-blind, positive-controlled trial, OLP patients with erosive lesions received betamethasone mouthwash (0.137 mg/mL) or dexamethasone mouthwash (0.181 mg/mL) three times daily for 2 or 4 weeks and were followed up for 3 months to observe recurrence. The primary outcome was the week-2 reduction in erosive area.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">Fifty-seven participants were randomized to betamethasone (<italic>n</italic> = 29) and dexamethasone (<italic>n</italic> = 28). At week 2, participants using betamethasone (<italic>n</italic> = 28) experienced a greater reduction in erosive area than gargling with dexamethasone (<italic>n</italic> = 26). Similarly, secondary outcomes, including the healing proportion of erosions, reduced pain level, reduction in atrophic area, Thongprasom score, and recurrence interval, showed the superiority of betamethasone. At week 4, betamethasone (<italic>n</italic> = 7) was not superior to dexamethasone (<italic>n</italic> = 15) in further reducing lesional area and pain level. No serious adverse events were documented.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">The 0.137 mg/mL compound betamethasone mouthwash exhibited significant efficacy in rapidly enhancing erosion healing within 2 weeks and extending the recurrence interval with a good safety profile.</p>
                </sec>
                <sec>
                  <title>Clinical relevance</title>
                  <p id="Par5">This study proved the significant efficacy of short-course 0.137 mg/mL betamethasone mouthwash therapy for treating erosion and pain, providing a novel topical agent for patients with severe EOLP.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par6">This study was prospectively registered at the International Clinical Trials Registry Platform (<ext-link ext-link-type="uri" xlink:href="https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR1800016507">ChiCTR1800016507</ext-link>) on 5 June 2018.</p>
                </sec>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1007/s00784-023-05051-w.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Oral lichen planus</kwd>
                <kwd>Betamethasone</kwd>
                <kwd>Dexamethasone</kwd>
                <kwd>Efficacy</kwd>
                <kwd>Randomized controlled trial</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par7">Lichen planus is a common chronic inflammatory mucocutaneous disease with unclear etiology. The lesions often involve only the oral mucosa (oral lichen planus, OLP), characterized by multisite or bilateral symmetrical white reticular lesions sometimes accompanied by atrophic, bullous, or erosive lesions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The global incidence of OLP is approximately 1.01%, and erosive oral lichen planus (EOLP) accounts for 32.46% of cases [<xref ref-type="bibr" rid="CR3">3</xref>]. Unlike self-limited cutaneous lesions, oral erosions are difficult to self-heal and susceptible to recurrence, frequently causing painful symptoms in patients.[<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] The World Health Organization (WHO) has considered OLP to be an oral potentially malignant disorder since 2007 [<xref ref-type="bibr" rid="CR4">4</xref>]. As a potential risk factor in oral carcinogenesis, 1.05â2.85% of erosions may transform into malignant tumors, imposing a heavy psychological burden on patients with EOLP [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
              <p id="Par8">According to recent European S1 guidelines, OLP treatment options comprise first-line, second-line, and third-line treatments [<xref ref-type="bibr" rid="CR2">2</xref>]. Topical steroids are the preferred drugs against localized erosions, such as clobetasol, fluocinonide, triamcinolone, dexamethasone, and betamethasone [<xref ref-type="bibr" rid="CR6">6</xref>], while for widespread or multisite erosions of severe EOLP, the most effective medicines are oral corticosteroids [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. For severe EOLP patients with contraindications or recalcitrant erosions to oral prednisone or methylprednisolone, the remaining first-line treatments, cyclosporine [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] and retinoids [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], and some second-line systematic treatments, such as azathioprine [<xref ref-type="bibr" rid="CR12">12</xref>], methotrexate [<xref ref-type="bibr" rid="CR13">13</xref>] and mycophenolate mofetil [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], can be considered. However, the efficacy of most systemic therapies has not been validated by randomized controlled trials (RCTs), and long-term use could cause a spectrum of side effects, such as hepatotoxicity, nephrotoxicity, myelotoxicity and increased risk of infection or malignant transformation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Among the first-line treatments, topical steroids have been investigated in several prospective studies for treating severe EOLP patients, 42.9 to 93.3% of whom had a good response in decreasing clinical scores and 64.3 to 93.7% of whom had pain relief [<xref ref-type="bibr" rid="CR16">16</xref>â<xref ref-type="bibr" rid="CR21">21</xref>]. It is worth noting that the concentration of topical steroids, commonly used in dermatology, might be so high as to cause systemic absorption since the oral mucosa is 4 to 4000 times as permeable as the skin [<xref ref-type="bibr" rid="CR22">22</xref>]. In addition, long-term application, usually for 3 to 6 months, leaves patients susceptible to fungal infections, mucosal atrophy, and glucocorticoid resistance [<xref ref-type="bibr" rid="CR23">23</xref>â<xref ref-type="bibr" rid="CR26">26</xref>]. To prevent oral candidiasis secondary to immunosuppression, antifungal agents are often associated with topical corticosteroids, such as miconazole and chlorhexidine [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
              <p id="Par9">Hence, there is a clinical need for an effective topical agent with a short course of treatment and low concentration to reduce systemic and local side effects. We previously reported the safety and noticeable efficacy of the intralesional compound betamethasone for the treatment of EOLP, and we assumed that soluble betamethasone sodium phosphate (BSP) and slightly soluble betamethasone dipropionate (BD) cooperatively exerted rapid and sustained anti-inflammatory effects [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. From this, we proposed a novel hypothesis that short-course, low-concentration betamethasone mouthwash had a dual effect on facilitating fast erosion healing and prolonging the recurrence-free period. We therefore designed this RCT to compare the short-term efficacy of 0.137 mg/mL betamethasone mouthwash for the treatment of severe EOLP with dexamethasone, the most frequently used glucocorticoid mouthwash [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
            </sec>
            <sec id="Sec2">
              <title>Materials and methods</title>
              <sec id="Sec3">
                <title>Study design and participants</title>
                <p id="Par10">This investigator-initiated, single-center, randomized, investigator-blind, positive-controlled trial was approved by the Ethical Committee of the West China Hospital of Stomatology, Sichuan University (granted number: WCHSIRB-D-2018-046-R) and was prospectively registered at the International Clinical Trials Registry Platform (ChiCTR1800016507). This study was conducted in accordance with the Declaration of Helsinki. Signed informed consent was obtained from all participants. There was no critical change to methods or outcomes after trial commencement.</p>
                <p id="Par11">Participants diagnosed with OLP by clinical and histopathological analysis at West China Hospital of Stomatology according to modified WHO criteria were sequentially enrolled in our department [<xref ref-type="bibr" rid="CR30">30</xref>]. Inclusion criteria were as follows: (a) aged 18 to 60 years; (b) single erosion area â¥ 1 cm<sup>2</sup>, or total area of multiple erosions â¥ 1 cm<sup>2</sup>, or erosion area &lt; 1cm<sup>2</sup> with the total area of surrounding atrophic lesions â¥ 1 cm<sup>2</sup> [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]; (c) disease duration â¥ 2 months; and (d) volunteered to follow up.</p>
                <p id="Par12">Exclusion criteria were (a) allergic to glucocorticoids; (b) received systemic therapy for 3 months or topical treatment for 2 weeks before participating; (c) had comorbidities, such as uncontrolled hypertension, cardiovascular diseases, blood diseases, neuropsychiatric disorders, or other systemic diseases requiring taking medications; (d) presence of lichenoid lesions caused by amalgam fillings or certain drugs; (e) extraoral lesions of lichen planus; (f) other oral mucosal diseases; and (g) pregnant or breast-feeding women.</p>
                <p id="Par13">Withdrawal criteria were as follows: (a) lost to follow-up; (b) occurrence of adverse events (AEs) determined by the investigator to be unfit for participation; (c) unwilling to keep on participating in the study; (d) developing oral or systemic diseases in the exclusion criteria after the intervention; and (e) poor compliance.</p>
              </sec>
              <sec id="Sec4">
                <title>Intervention</title>
                <p id="Par14">All participants received 5 mL of compound betamethasone mouthwash (0.137 mg/mL, experimental group) or dexamethasone mouthwash (0.181 mg/mL, control group), applied thrice daily (3 min each) for 2 or 4 weeks.</p>
                <p id="Par15">The betamethasone mouthwash was prepared by diluting 1 mL of compound betamethasone injection (DIPROSPANÂ®, MSD Merck Sharp &amp;Dohme AG, Luzern, Switzerland) containing 6.43 mg BD (equivalent to 5 mg betamethasone) and 2.63 mg BSP (equivalent to 2 mg betamethasone) with 50 mL of sterile water (dilution ratio 1:50). The dexamethasone mouthwash was prepared by diluting 1 mL of dexamethasone sodium phosphate (DSP) injection (Kingyork Pharmaceutical Co., Ltd, Tianjin, China) containing 5 mg DSP (equivalent to 3.8 mg dexamethasone) with 20 mL of sterile water (dilution ratio 1:20).</p>
                <p id="Par16">All patients were instructed on how to measure volume both in written and oral forms. Compliance was evaluated by the gargling days until dosage for 2 weeks was used up, and 14 Â± 2 days was regarded as good compliance. Drinking and eating were forbidden for 30 min after gargling. Spicy foods and other treatments, except for rescue medicine, were not allowed during treatment. In addition, 0.12% chlorhexidine mouthwash was applied three times daily before intervention against oral candidiasis in both groups.</p>
                <p id="Par17">The trial included two stages of a 2-week treatment period and one stage of a 3-month observation period for recurrence. When patients were free of erosion and pain symptoms after the first 2 weeks of treatment, they discontinued intervention and entered the observation period. If not, the second 2-week treatment was given. The participants without erosion and pain after 4 weeks of treatment also entered the observation period. If the erosions were still visible at week 4, alternative therapy was given, such as oral glucocorticoids and intralesional injection [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p>
              </sec>
              <sec id="Sec5">
                <title>Outcomes</title>
                <p id="Par18">The primary outcome was the week-2 reduction in erosive area, defined as the difference in erosive area between baseline and week 2. The lesional area was calculated by multiplying the greatest length diameter (mm) and vertical greatest width diameter (mm) using a calibrated dental probe [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p>
                <p id="Par19">Secondary outcomes were as follows. (a) Week-4 reduction in erosive area, the erosive area difference between week 2 and week 4. (b) Reduced pain level, using a numeric rating scale (NRS) [<xref ref-type="bibr" rid="CR35">35</xref>] to estimate the difference in spontaneous pain before and after treatment. (c) Healing proportion of erosions, presented as participants with erosion healing after treatment/allocated participants Ã 100%. (d) Reduction in atrophic area and reticular area. (e) Thongprasom sign score, ranging from 0 to 5 [<xref ref-type="bibr" rid="CR31">31</xref>]. (f) Recurrence, including the recurrence interval, recurrence erosive area, and recurrence rate, which was defined as the proportion of participants who experienced recurrent erosions within 3 months.</p>
                <p id="Par20">Safety outcomes included the incidence and severity of AEs. At each subsequent clinic visit, participants were asked to report any local or systemic discomfort and abnormality. We carefully checked for oral fungal infection signs and took oral swabs for direct microscopic examination of fungi before and after therapy.</p>
              </sec>
              <sec id="Sec6">
                <title>Randomization and blinding</title>
                <p id="Par21">Participants were randomized 1:1 to the experimental or control group according to the allocation sequence, which was randomly generated by SPSS 20.0.0 (IBM, Armonk, USA) and hidden in enclosed opaque envelopes. Only one investigator not engaged in clinical visits could access the sequence. As a participant was recruited, an envelope was opened sequentially by investigator A, who was not involved in the outcome assessment. Another investigator B blinded to the intervention information was responsible for the outcome measurement [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p>
              </sec>
              <sec id="Sec7">
                <title>Statistical analysis</title>
                <p id="Par22">By reference to our pre-experimental results, the mean difference (MD) of the primary outcome in both groups was assumed to be 18 cm<sup>2</sup>, with a standard deviation (SD) of 30. For 90% power at a one-sided 2.5% significance level, allowing for 20% withdrawal, a sample size of 50 (25 per group) was needed.</p>
                <p id="Par23">Analyses were conducted by two independent investigators who were blinded to the allocation and outcome evaluation using SPSS 22.0.0 and STATA 15.1 (Stata Corporation, College Station, TX, USA). Quantitative data are presented as the median (Q1 [first quartile]âQ3 [third quartile]) and were analyzed using the <italic>t</italic> test (paired <italic>t</italic> test or independent <italic>t</italic> test) or rank-sum test (Wilcoxon test or Mann-Whitney <italic>U</italic> test). Categorical data are expressed as numbers (%) and were analyzed by the Pearson chi-square test or Fisherâs exact test. The main analysis was carried out on the per-protocol (PP) principle to evaluate the actual efficacy of cases without protocol violations or unassessable outcomes.</p>
                <p id="Par24">For the primary outcome, MD with 95% confidence interval (95% CI) and <italic>p</italic> value before and after each treatment arm (within-group comparison) or between two groups before and after treatment (between-group comparison) was calculated. If the reduction in lesional area was negative in some aggravating cases, the data of reduction area was adjusted as zero, and the adjusted MD was presented. Secondary outcomes of quantitative data were analyzed by similar methods. For the healing proportion of erosions and recurrence rate, the risk ratio (RR) with 95% CI and <italic>p</italic> value was calculated.</p>
                <p id="Par25">Intention-to-treat (ITT) analyses will be performed as sensitivity analyses for the results of PP analyses. The missing data were regarded as invalid responses to treatment, and the method of last observation carried forward (LOCF) was applied to supplement the missing data [<xref ref-type="bibr" rid="CR36">36</xref>]. Logistic regression was applied to analyze local and systemic risk factors for erosion healing, including erosive area (mm<sup>2</sup>), number of oral erosions, number of affected sides, lesion position (buccal mucosa and/or tongue), Thongprasom score, perilesional supragingival dental calculus (presence or absence), age, and sex, and the forest plot was generated by R language 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria). A two-sided <italic>p</italic> value &lt; 0.05 was considered statistically significant.</p>
              </sec>
            </sec>
            <sec id="Sec8">
              <title>Results</title>
              <sec id="Sec9">
                <title>Recruitment and participant characteristics</title>
                <p id="Par26">From July 2018 to June 2021, 68 consented to participate in this trial, 57 of whom were eligible; 29 patients were randomized to betamethasone, and 28 were randomized to the control (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Baseline characteristics were well balanced between the treatment groups (Table <xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT flow chart (<bold>a</bold>) and design schematic (<bold>b</bold>) of this randomized controlled trial. ITT, intention to treat; PP, per-protocol</p></caption><graphic xlink:href="784_2023_5051_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of the 57 patients randomized to receive dexamethasone or betamethasone</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Baseline</th><th>BET (<italic>n</italic> = 29)</th><th>DEX (<italic>n</italic> = 28)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Male sex (<italic>n</italic>, %)</td><td>9 (31.03%)</td><td>12 (42.86%)</td><td>0.36<sup>a</sup></td></tr><tr><td>Age (years)</td><td>54.0 [47.0; 58.5]</td><td>49.0 [41.5; 59.5]</td><td>0.19<sup>b</sup></td></tr><tr><td>Duration of OLP (months)</td><td>8.0 [3.0; 13.5]</td><td>6.0 [3.0; 12.0]</td><td>0.48<sup>b</sup></td></tr><tr><td>Number of oral erosions</td><td>3.0 [2.0; 4.5]</td><td>3.0 [2.0; 4.0]</td><td>0.88<sup>b</sup></td></tr><tr><td>Number of affected sides</td><td>2.0 [1.0; 2.0]</td><td>2.0 [1.0; 2.0]</td><td>0.87<sup>c</sup></td></tr><tr><td>Lesion position (<italic>n</italic>, %)</td><td/><td/><td rowspan="4">0.70<sup>a</sup></td></tr><tr><td>âBuccal mucosa</td><td>22 (75.9%)</td><td>19 (67.9%)</td></tr><tr><td>âTongue</td><td>3 (10.3%)</td><td>5 (17.9%)</td></tr><tr><td>âBuccal mucosa and tongue</td><td>4 (13.8%)</td><td>4 (14.3%)</td></tr><tr><td>Thongprasom score</td><td>4.0 [4.0; 4.0]</td><td>4.0 [4.0; 4.0]</td><td>0.42<sup>c</sup></td></tr><tr><td>Oral erosive surface (mm<sup>2</sup>)</td><td>50.0 [17.5; 85.5]</td><td>36.0 [21.3; 65.8]</td><td>0.56<sup>b</sup></td></tr><tr><td>Oral atrophic surface (mm<sup>2</sup>)</td><td>172.0 [108.5; 267.3]</td><td>184.5 [106.5; 291.9]</td><td>0.80<sup>b</sup></td></tr><tr><td>Oral reticular surface (mm<sup>2</sup>)</td><td>771.0 [470.0; 1749.5]</td><td>1072.0 [900.0; 1415.0]</td><td>0.18<sup>b</sup></td></tr><tr><td>Oral pain (NRS score)</td><td>3.0 [2.0; 3.0]</td><td>3.0 [2.0; 3.0]</td><td>0.75<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Qualitative data are presented as numbers (%), and quantitative data are expressed as the median and interquartile range [first quartile; third quartile]. <sup>a</sup>Pearson chi-square test; <sup>b</sup>Mann-Whitney test; <sup>c</sup>Independent samples <italic>t</italic> test. <italic>BET</italic> betamethasone, <italic>DEX</italic> dexamethasone, <italic>NRS</italic> numeric rating scale</p></table-wrap-foot></table-wrap></p>
                <p id="Par27">At week 2, one betamethasone and two control participants withdrew from treatment due to time conflicts, and 28 betamethasone (96.6%) and 26 control (92.9%) patients attended the visit. The median gargling day was 14.0 [13.0;14.0] for betamethasone and 14.0 [14.0;15.0] for the control, indicating good compliance of all participants. Nineteen betamethasone and seven control patients achieved the disappearance of erosion and pain. However, three control participants complained of no treatment response (reduction of erosive surface â¤ 0 mm<sup>2</sup>) and asked for alternative therapy. Thus, nine betamethasone (31.0%) and sixteen control (57.1%) patients who had no healing erosions continued the second 2-week treatment, but two betamethasone and one control patient were lost to follow-up at week 4. In total, nine participants (15.8%) withdrew from this trial.</p>
              </sec>
              <sec id="Sec10">
                <title>Week-2 reduction in erosive area</title>
                <p id="Par28">At week 2, significant effectiveness in reducing erosive area was found in both the betamethasone (<italic>n</italic> = 28; MD 44.77, 95% CI 26.95â62.58; <italic>p</italic> &lt; 0.001) and control groups (<italic>n</italic> = 26; adjusted MD 27.60, 95% CI 2.47â52.72; <italic>p</italic> = 0.001) (Table <xref rid="Tab2" ref-type="table">2</xref>). However, the MD of the between-group comparison revealed the superiority of betamethasone over the control in rapidly reducing erosive area (21.65, 95% CI 2.36â40.94; <italic>p</italic> = 0.022) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a and Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>The PP analysis of lesional area and pain level of each group before and after the treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Intervention</th><th>Erosive area (mm<sup>2</sup>)</th><th>Atrophic area (mm<sup>2</sup>)</th><th>Reticular area (mm<sup>2</sup>)</th><th>Pain level (NRS score)</th></tr></thead><tbody><tr><td colspan="6">After the first 2-week treatment (week 2)</td></tr><tr><td rowspan="4">âBET (<italic>n</italic> = 28)</td><td>Week 0</td><td>44.0 [17.3; 82.3]</td><td>170.5 [106.8;280.9]</td><td>828.0 [465.0; 1872.3]</td><td>3.0 [2.0; 3.0]</td></tr><tr><td>Week 2</td><td>0.0 [0.0; 9.5]</td><td>38.0 [10.1; 88.3]</td><td>485.0 [217.5; 973.0]</td><td>0.0 [0.0; 0.0]</td></tr><tr><td>Unadjusted MD (95% CI)</td><td>44.77 (26.95 to 62.58)</td><td>182.23 (103.53 to 260.93)</td><td>419.91 (45.94 to 793.88)</td><td>2.54 (2.16 to 2.92)</td></tr><tr><td><italic>p</italic> value<sup>a</sup></td><td>&lt;0.001<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td></tr><tr><td rowspan="5">âDEX (<italic>n</italic> = 26)</td><td>Week 0</td><td>36.0 [19.8; 57.3]</td><td>177.0 [105.0; 280.6]</td><td>1101.0 [900.0; 1446.5]</td><td>2.5 [2.0; 3.0]</td></tr><tr><td>Week 2</td><td>19.0 [0.0; 52.6]</td><td>85.0 [48.8; 151.5]</td><td>960.5 [628.8; 1131.8]</td><td>2.0 [0.0; 2.0]</td></tr><tr><td>Unadjusted MD (95% CI)</td><td>23.12 (â2.40 to 48.63)</td><td>89.75 (28.60 to 150.90)</td><td>233.04 (2.53 to 463.54)</td><td>1.27 (0.65 to 1.89)</td></tr><tr><td>Adjusted MD (95% CI)</td><td>27.60 (2.47 to 52.72)</td><td>102.67 (51.40 to 153.95)</td><td>236.46 (7.11 to 465.82)</td><td>1.38 (0.82 to 1.94)</td></tr><tr><td><italic>p</italic> value<sup>a</sup></td><td>0.001<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td></tr><tr><td colspan="6">After the second 2-week treatment (week 4)</td></tr><tr><td rowspan="4">âBET (<italic>n</italic> = 7)</td><td>Week 2</td><td>18.0 [8.0;71.0]</td><td>110.0 [32.0; 120.0]</td><td>560.0 [120.5; 1125.0]</td><td>1.0 [0.0; 2.0]</td></tr><tr><td>Week 4</td><td>9.0 [0.0;24.0]</td><td>56.0 [0.0; 63.0]</td><td>560.0[63.0; 820.0]</td><td>0.0 [0.0; 2.0]</td></tr><tr><td>Unadjusted MD (95% CI)</td><td>17.46 (â9.40 to 44.33)</td><td>57.14 (7.68 to 106.60)</td><td>240.36 (â325.63 to 806.34)</td><td>0.29 (â0.74 to 1.31)</td></tr><tr><td><italic>p</italic> value<sup>a</sup></td><td>0.089<sup>c</sup></td><td>0.008<sup>c</sup></td><td>0.189<sup>c</sup></td><td>0.317<sup>b</sup></td></tr><tr><td rowspan="5">âDEX (<italic>n</italic> = 15)</td><td>Week 2</td><td>32.5 [5.0;72.0]</td><td>103.5 [62.0; 156.0]</td><td>957.0 [580.0; 1065.0]</td><td>2.0 [1.0; 2.0]</td></tr><tr><td>Week 4</td><td>8.0 [0.0; 57.0]</td><td>55.0 [24.0; 180.0]</td><td>765.0[500.0; 936.0]</td><td>1.0 [0.0; 1.0]</td></tr><tr><td>Unadjusted MD (95% CI)</td><td>8.20 (â22.74 to 39.14)</td><td>â50.30 (â203.31 to 102.71)</td><td>82.93 (â291.21 to 457.08)</td><td>0.87 (0.32 to 1.42)</td></tr><tr><td>Adjusted MD (95% CI)</td><td>22.10 (â4.99 to 49.19)</td><td>48.90 (â4.99 to 102.80)</td><td>198.80 (â125.67 to 523.27)</td><td>0.93 (0.41 to 1.46)</td></tr><tr><td><italic>p</italic> value<sup>a</sup></td><td>0.532<sup>c</sup></td><td>0.152<sup>b</sup></td><td>0.074<sup>b</sup></td><td>0.003<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p>Data are expressed as the median and interquartile range [first quartile; third quartile]. <sup>a</sup>The within-group differences were compared between the start and the end of treatment of each group. <sup>b</sup>Wilcoxon signed ranks test. <sup>c</sup>Paired sample <italic>t</italic> test. <italic>BET</italic> betamethasone, <italic>DEX</italic> dexamethasone, <italic>MD</italic> mean difference, <italic>NRS</italic> numeric rating scale, <italic>PP</italic> per-protocol</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Median erosive area and the number of erosion-free cases during treatment with betamethasone (BET) or dexamethasone (DEX) and a 3-month off-treatment period. <bold>a</bold> Changes in patients completing the first 2-week treatment and the recurrence of 2-week healing patients. <bold>b</bold> Changes in patients receiving the second 2-week therapy and the recurrence of 4-week healing patients</p></caption><graphic xlink:href="784_2023_5051_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>The comparison of lesional area and pain level between the two groups before and after the treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Intervention</th><th>Reduction in erosive area (mm<sup>2</sup>)</th><th>Reduction in atrophic area (mm<sup>2</sup>)</th><th>Reduction in reticular area (mm<sup>2</sup>)</th><th>Reduced pain level (NRS score)</th></tr></thead><tbody><tr><td colspan="5">PP analysis at week 2</td></tr><tr><td>âBET (<italic>n</italic> = 28)</td><td>31.6 [16.8; 75.5]</td><td>125.5 [81.4; 187.9]</td><td>194.0 [136.0; 710.3]</td><td>2.0 [2.0; 3.0]</td></tr><tr><td>âDEX (<italic>n</italic> = 26)</td><td>18.0 [7.5; 38.0]</td><td>69.0 [36.3; 161.3]</td><td>196.5 [61.5; 298.8]</td><td>1.0 [1.0; 2.0]</td></tr><tr><td>âMD (95% CI)</td><td>21.65 (2.36 to 40.94)</td><td>92.48 (7.74 to 177.22)</td><td>186.87 (â8.43 to 382.17)</td><td>1.27 (0.69 to 1.84)</td></tr><tr><td><italic>p</italic> value<sup>a</sup></td><td>0.022<sup>b</sup></td><td>0.013<sup>b</sup></td><td>0.166<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td></tr><tr><td colspan="5">ITT analysis at week 2</td></tr><tr><td>âBET (<italic>n</italic> = 29)</td><td>31.0 [16.1; 72.0]</td><td>123.0 [74.0; 184.8]</td><td>193.0 [126.0; 698.5]</td><td>2.0 [2.0; 3.0]</td></tr><tr><td>âDEX (<italic>n</italic> = 28)</td><td>15.5 [3.0; 36.0]</td><td>68.0 [30.3; 147.3]</td><td>168.0 [23.3; 287.3]</td><td>1.0 [0.25; 2.0]</td></tr><tr><td>âMD (95% CI)</td><td>21.76 (3.17 to 40.34)</td><td>92.61 (10.47 to 174.74)</td><td>189.04 (â1.29 to 379.36)</td><td>1.27 (0.69 to 1.85)</td></tr><tr><td>â<italic>p</italic> value<sup>a</sup></td><td>0.017<sup>b</sup></td><td>0.010<sup>b</sup></td><td>0.121<sup>b</sup></td><td>&lt;0.001<sup>b</sup></td></tr><tr><td colspan="5">PP analysis at week 4</td></tr><tr><td>âBET (<italic>n</italic> = 7)</td><td>8.0 [0.0; 32.0]</td><td>60.0 [25.0; 91.0]</td><td>57.5 [12.0; 305.0]</td><td>0.0 [0.0; 0.0]</td></tr><tr><td>âDEX (<italic>n</italic> = 15)</td><td>14.0 [0.0; 36.0]</td><td>36.0 [0.0; 90.0]</td><td>70.0 [0.0; 390.0]</td><td>1.0 [0.0; 2.0]</td></tr><tr><td>âMD (95% CI)</td><td>9.26 (â20.99 to 39.52)</td><td>107.44 (â46.40 to 261.28)</td><td>157.42 (â253.84 to 568.69)</td><td>â0.58 (â1.31 to 0.15)</td></tr><tr><td>â<italic>p</italic> value<sup>a</sup></td><td>&gt;0.999<sup>b</sup></td><td>0.407<sup>b</sup></td><td>&gt;0.999<sup>b</sup></td><td>0.142<sup>b</sup></td></tr><tr><td colspan="5">ITT analysis at week 4</td></tr><tr><td>âBET (<italic>n</italic> = 10)</td><td>1.13 [0.0; 21.5]</td><td>36.0 [0.0; 69.3]</td><td>15.5 [0.0; 154.3]</td><td>0.0 [0.0; 0.0]</td></tr><tr><td>âDEX (<italic>n</italic> = 21)</td><td>2.0 [0.0; 28.3]</td><td>11.0 [0.0; 57.0]</td><td>21.0 [0.0; 250.5]</td><td>0.0 [0.0; 1.0]</td></tr><tr><td>âMD (95% CI)</td><td>6.37 (â15.0 to 28.24)</td><td>75.93 (â34.52 to 186.37)</td><td>109.01 (â185.34 to 403.36)</td><td>â0.46 (â1.02 to 0.09)</td></tr><tr><td>â<italic>p</italic> value<sup>a</sup></td><td>0.917<sup>b</sup></td><td>0.492<sup>b</sup></td><td>0.819<sup>b</sup></td><td>0.124<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Data are expressed as the median and interquartile range [first quartile; third quartile]. <sup>a</sup>The between-group differences were compared between the betamethasone and dexamethasone groups. <sup>b</sup>Mann-Whitney test. <italic>BET</italic> betamethasone, <italic>DEX</italic> dexamethasone,<italic>ITT</italic> intention-to-treat analysis, <italic>MD</italic> mean difference, <italic>NRS</italic> numeric rating scale, <italic>PP</italic> per-protocol</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec11">
                <title>Week-4 reduction in erosive area</title>
                <p id="Par29">Neither the MD of betamethasone (17.46, 95% CI â9.40 to 44.33; <italic>p</italic> = 0.089) nor the control (adjusted MD 22.10, 95% CI â4.99 to 49.19; <italic>p</italic> = 0.532) showed a further significant reduction in erosive area before and after the second 2-week treatment (Table <xref rid="Tab2" ref-type="table">2</xref>). Betamethasone (<italic>n</italic> = 7) did not demonstrate the superiority of narrowing erosive area over control (<italic>n</italic> = 15) in weeks 3 to 4 (MD 9.26, 95% CI â20.99 to 39.52; <italic>p</italic> &gt; 0.999) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b and Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
              </sec>
              <sec id="Sec12">
                <title>Healing proportion of erosions</title>
                <p id="Par30">At week 2, the healing proportion of erosions in betamethasone patients (<italic>n</italic> = 19, 67.9%) was significantly higher than that in control patients (<italic>n</italic> = 7, 26.9%) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), and the RR between the treatment arms was 2.52 (95% CI 1.27-4.99; <italic>p</italic> = 0.003) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). At week 4, a significant between-group difference in the healing proportion of erosions was not observed (RR 1.61, 95% CI 0.48â5.33; <italic>p</italic> = 0.630) (Table <xref rid="Tab4" ref-type="table">4</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Significant efficacy of 2 weeks of betamethasone mouthwash for severe erosive oral lichen planus. <bold>a</bold>, <bold>b</bold> Two participants suffered extensive erosions surrounded by atrophic and reticular lesions on the buccal mucosa before treatment. <bold>c</bold>, <bold>d</bold> Their erosive lesions completely healed, atrophic lesions nearly disappeared and reticular lesions significantly regressed at week 2</p></caption><graphic xlink:href="784_2023_5051_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab4"><label>Table 4</label><caption><p>Analysis of the healing proportion of erosions and recurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Intervention</th><th colspan="2">Healing proportion of erosions</th><th colspan="2">Recurrence</th></tr><tr><th>PP analysis (%)</th><th>ITT analysis (%)</th><th>Participants<sup>a</sup> (%)</th><th>Interval day<sup>a,b</sup> (Mean Â± SD)</th></tr></thead><tbody><tr><td colspan="5">Participants receiving 2-week treatment</td></tr><tr><td>âBET</td><td>19/28 (67.9%)</td><td>19/29 (65.5%)</td><td>6/19 (31.6%)</td><td>40.3 Â± 14.7</td></tr><tr><td>âDEX</td><td>7/26 (26.9%)</td><td>7/28 (25.0%)</td><td>4/7 (57.1%)</td><td>20.8 Â± 9.4</td></tr><tr><td>âEffect size (95% CI)</td><td>RR 2.52 (1.27â4.99)</td><td>RR 2.62 (1.31â5.24)</td><td>RR 0.55 (0.22â1.39)</td><td>MD 19.50 (4.56â34.44)</td></tr><tr><td>â<italic>p</italic> value</td><td>0.003<sup>c</sup></td><td>0.002<sup>c</sup></td><td>0.369<sup>d</sup></td><td>0.048<sup>e</sup></td></tr><tr><td colspan="4">Participants receiving 4-week treatment</td><td/></tr><tr><td>âBET</td><td>3/7 (42.9%)</td><td>3/10 (30.0%)</td><td>0/3 (0.0%)</td><td>None</td></tr><tr><td>âDEX</td><td>4/15 (26.7%)</td><td>4/21 (19.0%)</td><td>2/4 (50.0%)</td><td>24.5 Â± 6.4</td></tr><tr><td>âEffect size (95% CI)</td><td>RR 1.61 (0.48â5.33)</td><td>RR 1.57 (0.43â5.74)</td><td>N/A</td><td>N/A</td></tr><tr><td>â<italic>p</italic> value</td><td>0.630<sup>d</sup></td><td>0.652<sup>d</sup></td><td>N/A</td><td>N/A</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>ITT analysis was not applicable. <sup>b</sup>The recurrence intervals were calculated by the period between the healing and recurrence of erosions at the same mucosal site. <sup>c</sup>Pearson chi-square test. <sup>d</sup>Fisher's exact test. <sup>e</sup>Independent samples <italic>t</italic> test. <italic>BET</italic> betamethasone, <italic>DEX</italic> dexamethasone, <italic>ITT</italic> intention-to-treat analysis, <italic>MD</italic> mean difference; <italic>N/A</italic> not applicable, <italic>PP</italic> per-protocol, <italic>RR</italic> risk ratio, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec13">
                <title>Reduced pain level</title>
                <p id="Par31">At week 2, the reduced pain level was significantly more pronounced in the betamethasone group than in the control group (MD 1.27, 95% CI 0.69â1.84; <italic>p</italic> &lt; 0.001). However, further pain reduction did not differ between the two groups during the second 2-week treatment (MD -0.58, 95% CI â1.31 to 0.15; <italic>p</italic> = 0.142) (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
              </sec>
              <sec id="Sec14">
                <title>Reduction in atrophic area and reticular area</title>
                <p id="Par32">Patients from the betamethasone group experienced a greater reduction in atrophic area than controls (MD 92.48, 95% CI 7.74â177.22; <italic>p</italic> = 0.013) at week 2 but no significant superiority over controls after the second 2-week treatment (MD 107.44, 95% CI â46.40 to 261.28; <italic>p</italic> = 0.407). While both groups could reduce the white reticular area, there was no evidence for the superiority of betamethasone over the control in reducing the reticular area at week 2 (MD 186.87, 95% CI â8.43 to 382.17; <italic>p</italic> = 0.166) or at week 4 (MD 157.42, 95% CI â253.84 to 568.69; <italic>p</italic> &gt; 0.999) (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
              </sec>
              <sec id="Sec15">
                <title>Thongprasom score</title>
                <p id="Par33">At week 2, the Thongprasom score in the betamethasone group (2.0 [2.0; 4.0]) showed a more significant reduction than that in the control group (4.0 [2.0; 4.0]) (MD â1.04, 95% CI â1.66 to â0.41; <italic>p</italic> = 0.002) while at week 4, there was no significant difference between the betamethasone (4.0 [1.0; 4.0]) and control groups (4.0 [2.0; 4.0]) (MD â0.74, 95% CI â1.97 to 0.48; <italic>p</italic> = 0.203).</p>
              </sec>
              <sec id="Sec16">
                <title>Recurrence</title>
                <p id="Par34">After the first 2-week treatment withdrawal, six betamethasone (31.6%) and four control (57.1%) patients had recurrence of erosions, with no significant between-group difference (RR 0.55, 95% CI 0.22â1.39). Patients from the betamethasone group experienced more erosion-free days than control patients (MD 19.50, 95% CI 4.56â34.44; <italic>p</italic> = 0.048) (Table <xref rid="Tab4" ref-type="table">4</xref>). No recurrence was detected in patients receiving 4 weeks of betamethasone, and two control patients experienced recurrence 20 and 29 days after dexamethasone withdrawal (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). At 3 months, the relapsed erosive areas in the betamethasone (<italic>n</italic> = 6) and dexamethasone (<italic>n</italic> = 6) groups were 8.5 [3.8; 26.1] and 13.3 [5.0; 23.5] mm<sup>2</sup>, respectively, and no significant difference was detected (MD 2.00, 95% CI â22.77 to 26.77; <italic>p</italic> = 0.872). Compared to prior to treatments, 70.9% [12.4%; 84.7%] of the reduction of relapsed erosion area after 3 months in betamethasone and 43.6% [12.5%; 79.2%] of reduction in control revealed no significant difference (MD 0.12, 95% CI â0.27 to 0.51; <italic>p</italic> = 0.571). In addition, six patients experiencing failure of dexamethasone mouthwash were cured with oral prednisone as an alternative, and three did not suffer from recurrence during the three-month follow-up period.</p>
              </sec>
              <sec id="Sec17">
                <title>Sensitivity analysis</title>
                <p id="Par35">The sensitivity analyses demonstrated that the <italic>p</italic> values of ITT analyses yielded similar results in primary and secondary outcomes (Table <xref rid="Tab3" ref-type="table">3</xref>, Figs <xref rid="MOESM1" ref-type="media">S1-S8</xref> and Table <xref rid="MOESM1" ref-type="media">S1</xref> in Supplementary Information).</p>
              </sec>
              <sec id="Sec18">
                <title>Risk factor analysis</title>
                <p id="Par36">Figure <xref rid="Fig4" ref-type="fig">4</xref> indicates that no significant local and systemic risk factors for 2-week erosion healing were identified (<italic>p</italic> &gt; 0.05) among the two treatment groups and all patients.<fig id="Fig4"><label>Fig. 4</label><caption><p>Forest plot of risk factors for erosion healing at week 2</p></caption><graphic xlink:href="784_2023_5051_Fig4_HTML" id="MO4"/></fig></p>
              </sec>
              <sec id="Sec19">
                <title>Safety</title>
                <p id="Par37">During the whole study period, no serious AEs were reported. Two betamethasone participants (6.9%) experienced slight dryness of the mouth, and one control participant (3.6%) had a buccal burning sensation. These symptoms occurred over the first 2-week period and resolved spontaneously within 1 week. No case of oral candidiasis was identified before and after treatment based upon both clinical signs and direct microscopic examination. Telephone follow-up was performed for six patients lost to follow-up, and no AE was reported.</p>
              </sec>
            </sec>
            <sec id="Sec20">
              <title>Discussion</title>
              <p id="Par38">The compound betamethasone mouthwash in this RCT was a novel pragmatic agent for people suffering from severe EOLP. We revealed for the first time that short-term use of low-concentration betamethasone mouthwash could effectively and safely promote erosion healing and symptom resolution. Compared with 0.181 mg/mL dexamethasone, 0.137 mg/mL betamethasone significantly reduced the erosive area, atrophic area, and pain level, increased the healing proportion of erosions, and prolonged the recurrence interval after 2 weeks of treatment. Sensitivity analyses produced consistent findings with the above results.</p>
              <p id="Par39">There is currently no published RCT comparing therapeutic effects on OLP lesions between betamethasone and dexamethasone, both long-acting corticosteroids. Dexamethasone 0.1â1.0 mg/mL mouthwash is widely used by OLP patients and has been designed as the positive control in many RCTs [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. According to glucocorticoid potency conversion, the dose of 0.137 mg betamethasone is approximately equivalent to the dose of 0.137â0.171 mg dexamethasone [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Considering the highest equivalent concentration to betamethasone (&gt; 0.171 mg/mL), efficacy and side effects of different concentrations reported in previous studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], and convenient dilution (ratio 1:20), we used 0.181 mg/mL dexamethasone as the control.</p>
              <p id="Par40">The risk factor analyses demonstrated that the efficacy of promoting erosion healing was not significantly influenced by potential local and systemic factors. The superiority of betamethasone over dexamethasone might be explained in the following three aspects. First, 0.137 mg/mL betamethasone exhibited much higher anti-inflammatory potency than 0.181 mg/mL dexamethasone. Although these two concentrations have not been included in the common potency ratings of topical corticosteroids [<xref ref-type="bibr" rid="CR42">42</xref>], it is generally known that 0.1% DSP cream, 0.1% betamethasone valerate (BMV) cream, and 0.05% BD cream are graded as low potency (Class VII), moderate potency (Class V), and high potency (Class III), respectively, indicating the higher potency of betamethasone than dexamethasone [<xref ref-type="bibr" rid="CR43">43</xref>]. Second, the compound betamethasone contains not only rapidly hydrolyzed BSP but also slowly metabolized BD that could be retained in erosions with less influence from saliva dilution and flush. Kopylova et al. found that betamethasone was detectable in all human urine samples (<italic>n</italic> =20) 28 days after DiprospanÂ® injection, and the complete elimination extended up to 48 days [<xref ref-type="bibr" rid="CR44">44</xref>]. Interestingly, the mean interval of erosion recurrence in our betamethasone patients was 40.3 days, suggesting that there was a longer hydrolysis period of BD in the mouth. Third, betamethasone might promote erosion recovery and reduce the patientâs symptoms by blocking the association of local lesions with systemic factors. Although not clear, the pathogenesis of OLP is generally considered T-cell-mediated epithelial barrier damage, which is responsible for the occurrence of local erosions and symptoms [<xref ref-type="bibr" rid="CR2">2</xref>]. Eating might be too painful for patients to receive a normal diet and adequate nutrition, causing weight loss, impairment in immune cell activity, and mental disorders, such as stress, anxiety, and depression [<xref ref-type="bibr" rid="CR2">2</xref>]. However, these psychological disorders as potential predisposing factors, contributing to activation of the host immunological responses toward local oral mucosa, might in turn cause exacerbation or recalcitrance of erosions, forming a vicious cycle [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. The rapid anti-inflammatory and pain-relieving actions of betamethasone help disrupt this vicious cycle as early as possible (and earlier than dexamethasone) (Fig. <xref rid="Fig5" ref-type="fig">5</xref>) and recover regular diet and nutrient uptake to maintain proper immune cell functionality [<xref ref-type="bibr" rid="CR47">47</xref>â<xref ref-type="bibr" rid="CR49">49</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><p>Schematic diagram of the vicious circle of oral lichen planus (OLP) between inflammation and psychological disorders. Patients with erosive OLP tend to suffer pain and psychological disorders. Stress results in the release of cortisol to promote Th2 cell differentiation and mast cell degranulation, secreting cytokines for basement membrane disruption. Depression and anxiety can elevate the levels of proinflammatory cytokines to enhance immune cell migration. Under the effects of psychological disorders, oral keratinocytes are more prone to be destroyed by cytotoxic T cells, aggravating inflammation, pain, and psychological disorders. The fast anti-inflammatory and analgesic effects of betamethasone could block this vicious cycle, facilitating a rapid healing process</p></caption><graphic xlink:href="784_2023_5051_Fig5_HTML" id="MO5"/></fig></p>
              <p id="Par41">Previous RCTs of applying topical betamethasone for EOLP have demonstrated its efficacy [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Hegarty et al. found that 22 patients had a mean 42.91% reduction in lesional area and a 29.73% reduction in visual analogue scale (VAS) after using a 6-week 0.005% BSP mouthrinse (0.5 mg tablet dissolved in 10 mL water) without AE. Ezzatt and Helmy showed that 15 patients receiving 0.1% BMV cream had significant reductions in clinical scoring (mean Â± SD 63.41% Â± 18.10%) and VAS (95.42% Â± 4.12%) at week 4, and 3 patients (20.0%) had a burning sensation or taste alteration. Samimi et al. detected that 0.05% BD ointment decreased the median erosive surface by 98.8% in 36 patients at month 3, 30 of whom (83.3%) reported AEs. The above findings suggested that the higher the concentration or potency of betamethasone, the better the anti-inflammatory effect and the higher the risk of AEs. In this study, 28 participants using 2 weeks of betamethasone had significant reductions in erosive area (88.16% Â± 22.52%) and pain level (92.26% Â± 19.50%), with a low rate of adverse reactions (7.1%), displaying its comparable efficacy of potent cream/ointment and good safety with short course and low concentration. Apart from the dual-acting betamethasone ingredients, the diluted liquid dosage not only had better access to all oral lesional sites to improve inflammation conditions adjacent to erosions but could rapidly contact erosions by directly releasing active molecules from water. In addition, mouthwash was much easier to use for any oral location and to reduce drug residence time in the mouth [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
              <p id="Par42">Both types of mouthwash had an acceptable safety profile. The reported dry mouth and burning sensation were common side effects of topical corticosteroids, which might be due to elevated nervous excitability [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Given the characteristics of high efficacy and low toxicity, betamethasone mouthwash could be a good candidate for the treatment of EOLP. The significant effects on enhancing erosion healing and extending the recurrence interval could reduce the revisit frequency of patients, especially during the current COVID-19 pandemic. We did not monitor betamethasone plasma levels with the long excretion period of BD and no impact on plasma cortisol levels in previous studies [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Of note, because most of the data followed non-normal distributions in this trial, the median might look dissimilar in the two arms, such as the erosive surface at baseline. Therefore, we also added the mean and SD in the supplementary figures (Figs. <xref rid="MOESM1" ref-type="media">S1-S8</xref>) to display data variability.</p>
              <p id="Par43">Although over 20 scoring systems have been used to grade the severity of OLP, such as the Thongprasom score and ReticularâErythematousâUlceration (REU) system, there is no gold standard scoring system or uniform definition of severe EOLP [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Referencing our previous method of defining refractory OLP [<xref ref-type="bibr" rid="CR55">55</xref>], we proposed the inclusion criteria for severe EOLP based on the classic Thongprasom score (â¥ 4) [<xref ref-type="bibr" rid="CR31">31</xref>] to facilitate quick identification by oral clinicians without complicated algorithmic summation.</p>
              <p id="Par44">The primary study limitation was the lack of patient-blind implementation with the different mouthwash physical appearances. Second, there was a larger difference in the number of patients receiving the second 2-week treatment because 67.9% of betamethasone patients entered the observation period after the first 2-week therapy. Additionally, using the calibrated dental probe to calculate lesional area (mm<sup>2</sup>) might yield some measurement bias, especially for lesions with irregular shapes. Therefore, we first divided an irregular lesion into several regular calculating parts and then combined their areas together to reduce measurement error. A software or scanner for automatically calculating oral lesional areas is clinically needed in the future.</p>
            </sec>
            <sec id="Sec21">
              <title>Conclusion</title>
              <p id="Par45">We identified for the first time the superiority of short-course, low-concentration compound betamethasone mouthwash over dexamethasone for rapidly enhancing erosion healing, relieving pain and effectively prolonging the interval of erosion recurrence. Both treatments were well tolerated. This trial suggested that 0.137 mg/mL compound betamethasone mouthwash is a novel, rapid-acting, and safe topical agent for patients with severe EOLP.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec22">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="784_2023_5051_MOESM1_ESM.docx">
                      <label>ESM 1</label>
                      <caption>
                        <p>Figure S1 Sensitivity analyses of lesional area and pain score after the first two weeks of betamethasone treatment. Figure S2 Sensitivity analyses of lesional area and pain score after the first two weeks of dexamethasone treatment. Figure S3 Sensitivity analyses of between-group differences after the first two weeks of treatment. Figure S4 Sensitivity analyses of lesional area and pain score after the second two-week treatment with betamethasone. Figure S5 Sensitivity analyses of lesional area and pain score after the second two-week treatment with dexamethasone. Figure S6 Sensitivity analyses of between-group differences after the second two-week treatment. Figure S7 Sensitivity analysis of Thongprasom score after the first and second two-week treatment. Figure S8 Forest plot of healing proportion of erosions and recurrence rate. Table S1 The ITT analysis of lesional area and pain level of each group before and after the treatment. (DOCX 569 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisherâs note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
              <fn>
                <p>Qingxiang Zeng and Yangfan Liu contributed equally to this work.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We would like to thank all the patients who participated in this study and who made this study possible. The figures were created with Kingsoft Office, GraphPad Prism, R language, BioRender, or STATA.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contribution</title>
              <p>Qingxiang Zeng: investigation, methodology, visualization, writingâoriginal draft, writingâreview and editing; Yangfan Liu: formal analysis, methodology, visualization, validation, software, writingâreview and editing; Shimeng Wang: formal analysis, methodology, visualization, writingâoriginal draft, writingâreview and editing; Houshang Wang: investigation, validation, writingâreview and editing; Shuang Yu: formal analysis, validation, writingâreview and editing; Fanglong Wu: investigation, resources, funding acquisition, writingâreview and editing; Jin Yang: data curation, funding acquisition, methodology, project administration, supervision, validation, visualization, writingâreview and editing; Hongmei Zhou: conceptualization, data curation, funding acquisition, methodology, project administration, supervision, writingâreview and editing, resources, investigation.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This work was financed by National Natural Science Foundation of China (No. 82071124, No. 82101028) and Natural Science Foundation of Sichuan Province (No. 2023NSFSC0552).</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>The data that support the findings of this trial and the full trial protocol are available from the corresponding authors upon reasonable request.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1">
                <title>Ethics approval and consent to participate</title>
                <p id="Par46">The study was approved by the Ethical Committee of the West China Hospital of Stomatology, Sichuan University (grant number: WCHSIRB-D-2018-046-R). Written informed consent was obtained from all participants before the intervention.</p>
              </notes>
              <notes id="FPar2" notes-type="COI-statement">
                <title>Conflict of interest</title>
                <p id="Par47">The authors declare no competing interests.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Solimani</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Forchhammer</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Schloegl</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ghoreschi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Meier</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Lichen planus - a clinical guide</article-title>
                  <source>J Dtsch Dermatol Ges</source>
                  <year>2021</year>
                  <volume>19</volume>
                  <issue>6</issue>
                  <fpage>864</fpage>
                  <lpage>882</lpage>
                  <?supplied-pmid 34139075?>
                  <pub-id pub-id-type="pmid">34139075</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ioannides</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Vakirlis</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kemeny</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Marinovic</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Massone</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Nast</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ronnevig</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ruzicka</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Cooper</surname>
                      <given-names>SM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology</article-title>
                  <source>J Eur Acad Dermatol Venereol</source>
                  <year>2020</year>
                  <volume>34</volume>
                  <issue>7</issue>
                  <fpage>1403</fpage>
                  <lpage>1414</lpage>
                  <pub-id pub-id-type="doi">10.1111/jdv.16464</pub-id>
                  <?supplied-pmid 32678513?>
                  <pub-id pub-id-type="pmid">32678513</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>GonzÃ¡lez-Moles</surname>
                      <given-names>MÃ</given-names>
                    </name>
                    <name>
                      <surname>Warnakulasuriya</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>GonzÃ¡lez-Ruiz</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>GonzÃ¡lez-Ruiz</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>AyÃ©n</surname>
                      <given-names>Ã</given-names>
                    </name>
                    <name>
                      <surname>Lenouvel</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ruiz-Ãvila</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Ramos-GarcÃ­a</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Worldwide prevalence of oral lichen planus: a systematic review and meta-analysis</article-title>
                  <source>Oral Dis</source>
                  <year>2021</year>
                  <volume>27</volume>
                  <issue>4</issue>
                  <fpage>813</fpage>
                  <lpage>828</lpage>
                  <pub-id pub-id-type="doi">10.1111/odi.13323</pub-id>
                  <?supplied-pmid 32144836?>
                  <pub-id pub-id-type="pmid">32144836</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Warnakulasuriya</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>NW</given-names>
                    </name>
                    <name>
                      <surname>van der Waal</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Nomenclature and classification of potentially malignant disorders of the oral mucosa</article-title>
                  <source>J Oral Pathol Med</source>
                  <year>2007</year>
                  <volume>36</volume>
                  <issue>10</issue>
                  <fpage>575</fpage>
                  <lpage>580</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1600-0714.2007.00582.x</pub-id>
                  <?supplied-pmid 17944749?>
                  <pub-id pub-id-type="pmid">17944749</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>GonzÃ¡lez-Moles</surname>
                      <given-names>MÃ</given-names>
                    </name>
                    <name>
                      <surname>Ruiz-Ãvila</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>GonzÃ¡lez-Ruiz</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>AyÃ©n</surname>
                      <given-names>Ã</given-names>
                    </name>
                    <name>
                      <surname>Gil-Montoya</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Ramos-GarcÃ­a</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Malignant transformation risk of oral lichen planus: a systematic review and comprehensive meta-analysis</article-title>
                  <source>Oral Oncol</source>
                  <year>2019</year>
                  <volume>96</volume>
                  <fpage>121</fpage>
                  <lpage>130</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.oraloncology.2019.07.012</pub-id>
                  <?supplied-pmid 31422203?>
                  <pub-id pub-id-type="pmid">31422203</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lodi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Manfredi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mercadante</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Carrozzo</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Interventions for treating oral lichen planus: corticosteroid therapies</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <year>2020</year>
                  <volume>2</volume>
                  <fpage>CD001168</fpage>
                  <?supplied-pmid 32108333?>
                  <pub-id pub-id-type="pmid">32108333</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Le Cleach</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Chosidow</surname>
                      <given-names>O</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical practice</article-title>
                  <source>Lichen planus. N Engl J Med</source>
                  <year>2012</year>
                  <volume>366</volume>
                  <issue>8</issue>
                  <fpage>723</fpage>
                  <lpage>732</lpage>
                  <?supplied-pmid 22356325?>
                  <pub-id pub-id-type="pmid">22356325</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Levell</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Munro</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Marks</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Severe lichen planus clears with very low-dose cyclosporin</article-title>
                  <source>Br J Dermatol</source>
                  <year>1992</year>
                  <volume>127</volume>
                  <issue>1</issue>
                  <fpage>66</fpage>
                  <lpage>67</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2133.1992.tb14836.x</pub-id>
                  <?supplied-pmid 1637703?>
                  <pub-id pub-id-type="pmid">1637703</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ho</surname>
                      <given-names>VC</given-names>
                    </name>
                    <name>
                      <surname>Gupta</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Ellis</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>Nickoloff</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Voorhees</surname>
                      <given-names>JJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment of severe lichen planus with cyclosporine</article-title>
                  <source>J Am Acad Dermatol</source>
                  <year>1990</year>
                  <volume>22</volume>
                  <issue>1</issue>
                  <fpage>64</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="doi">10.1016/0190-9622(90)70009-7</pub-id>
                  <?supplied-pmid 2298966?>
                  <pub-id pub-id-type="pmid">2298966</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hersle</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Mobacken</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Sloberg</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Thilander</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Severe oral lichen planus: treatment with an aromatic retinoid (etretinate)</article-title>
                  <source>Br J Dermatol</source>
                  <year>1982</year>
                  <volume>106</volume>
                  <issue>1</issue>
                  <fpage>77</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2133.1982.tb00904.x</pub-id>
                  <?supplied-pmid 7037037?>
                  <pub-id pub-id-type="pmid">7037037</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Camisa</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>CM</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment of oral erosive lichen planus with systemic isotretinoin</article-title>
                  <source>Oral Surg Oral Med Oral Pathol</source>
                  <year>1986</year>
                  <volume>62</volume>
                  <issue>4</issue>
                  <fpage>393</fpage>
                  <lpage>396</lpage>
                  <pub-id pub-id-type="doi">10.1016/0030-4220(86)90288-4</pub-id>
                  <?supplied-pmid 3464912?>
                  <pub-id pub-id-type="pmid">3464912</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Verma</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Mittal</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Manchanda</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Azathioprine for the treatment of severe erosive oral and generalized lichen planus</article-title>
                  <source>Acta Derm Venereol</source>
                  <year>2001</year>
                  <volume>81</volume>
                  <issue>5</issue>
                  <fpage>378</fpage>
                  <lpage>379</lpage>
                  <pub-id pub-id-type="doi">10.1080/000155501317140197</pub-id>
                  <?supplied-pmid 11800155?>
                  <pub-id pub-id-type="pmid">11800155</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lajevardi</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Ghodsi</surname>
                      <given-names>SZ</given-names>
                    </name>
                    <name>
                      <surname>Hallaji</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Shafiei</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Aghazadeh</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Akbari</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment of erosive oral lichen planus with methotrexate</article-title>
                  <source>J Dtsch Dermatol Ges</source>
                  <year>2016</year>
                  <volume>14</volume>
                  <issue>3</issue>
                  <fpage>286</fpage>
                  <lpage>293</lpage>
                  <?supplied-pmid 26972194?>
                  <pub-id pub-id-type="pmid">26972194</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wee</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Shirlaw</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Challacombe</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Setterfield</surname>
                      <given-names>JF</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients</article-title>
                  <source>Br J Dermatol</source>
                  <year>2012</year>
                  <volume>167</volume>
                  <issue>1</issue>
                  <fpage>36</fpage>
                  <lpage>43</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.10882.x</pub-id>
                  <?supplied-pmid 22309851?>
                  <pub-id pub-id-type="pmid">22309851</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Deen</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>McMeniman</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Mycophenolate mofetil in erosive genital lichen planus: a case and review of the literature</article-title>
                  <source>J Dermatol</source>
                  <year>2015</year>
                  <volume>42</volume>
                  <issue>3</issue>
                  <fpage>311</fpage>
                  <lpage>314</lpage>
                  <pub-id pub-id-type="doi">10.1111/1346-8138.12763</pub-id>
                  <?supplied-pmid 25583369?>
                  <pub-id pub-id-type="pmid">25583369</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gonzalez-Moles</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Morales</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Archilla</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Isabel</surname>
                      <given-names>IR-A</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez-Moles</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution</article-title>
                  <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
                  <year>2002</year>
                  <volume>93</volume>
                  <issue>3</issue>
                  <fpage>264</fpage>
                  <lpage>270</lpage>
                  <pub-id pub-id-type="doi">10.1067/moe.2002.120522</pub-id>
                  <?supplied-pmid 11925534?>
                  <pub-id pub-id-type="pmid">11925534</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hegarty</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Hodgson</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Lewsey</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Porter</surname>
                      <given-names>SR</given-names>
                    </name>
                  </person-group>
                  <article-title>Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus</article-title>
                  <source>J Am Acad Dermatol</source>
                  <year>2002</year>
                  <volume>47</volume>
                  <issue>2</issue>
                  <fpage>271</fpage>
                  <lpage>279</lpage>
                  <pub-id pub-id-type="doi">10.1067/mjd.2002.120922</pub-id>
                  <?supplied-pmid 12140475?>
                  <pub-id pub-id-type="pmid">12140475</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Corrocher</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Di Lorenzo</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Martinelli</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Mansueto</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Biasi</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Nocini</surname>
                      <given-names>PF</given-names>
                    </name>
                    <name>
                      <surname>Lombardo</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Fior</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Corrocher</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bambara</surname>
                      <given-names>LM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus</article-title>
                  <source>J Clin Periodontol</source>
                  <year>2008</year>
                  <volume>35</volume>
                  <issue>3</issue>
                  <fpage>244</fpage>
                  <lpage>249</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1600-051X.2007.01191.x</pub-id>
                  <?supplied-pmid 18269664?>
                  <pub-id pub-id-type="pmid">18269664</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Malhotra</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Khaitan</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Sethuraman</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Sharma</surname>
                      <given-names>VK</given-names>
                    </name>
                  </person-group>
                  <article-title>Betamethasone oral mini-pulse therapy compared with topical triamcinolone acetonide (0.1%) paste in oral lichen planus: a randomized comparative study</article-title>
                  <source>J Am Acad Dermatol</source>
                  <year>2008</year>
                  <volume>58</volume>
                  <issue>4</issue>
                  <fpage>596</fpage>
                  <lpage>602</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jaad.2007.11.022</pub-id>
                  <?supplied-pmid 18158199?>
                  <pub-id pub-id-type="pmid">18158199</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chauhan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>De</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Handa</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Narang</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Saikia</surname>
                      <given-names>UN</given-names>
                    </name>
                  </person-group>
                  <article-title>A prospective observational study to compare efficacy of topical triamcinolone acetonide 0.1% oral paste, oral methotrexate, and a combination of topical triamcinolone acetonide 0.1% and oral methotrexate in moderate to severe oral lichen planus</article-title>
                  <source>Dermatol Ther</source>
                  <year>2018</year>
                  <volume>31</volume>
                  <issue>1</issue>
                  <fpage>e12563</fpage>
                  <pub-id pub-id-type="doi">10.1111/dth.12563</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Samimi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Le Gouge</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Boralevi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Passeron</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Pascal</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Bernard</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Agbo-Godeau</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Leducq</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Fricain</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Vaillant</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Topical rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, double-blind, controlled study</article-title>
                  <source>J Eur Acad Dermatol Venereol</source>
                  <year>2020</year>
                  <volume>34</volume>
                  <issue>10</issue>
                  <fpage>2384</fpage>
                  <lpage>2391</lpage>
                  <pub-id pub-id-type="doi">10.1111/jdv.16324</pub-id>
                  <?supplied-pmid 32128907?>
                  <pub-id pub-id-type="pmid">32128907</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Varoni</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Molteni</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sardella</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Carrassi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Di Candia</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Gigli</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Lodi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Lodi</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacokinetics study about topical clobetasol on oral mucosa</article-title>
                  <source>J Oral Pathol Med</source>
                  <year>2012</year>
                  <volume>41</volume>
                  <issue>3</issue>
                  <fpage>255</fpage>
                  <lpage>260</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1600-0714.2011.01087.x</pub-id>
                  <?supplied-pmid 21950548?>
                  <pub-id pub-id-type="pmid">21950548</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sridharan</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sivaramakrishnan</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Interventions for oral lichen planus: a systematic review and network meta-analysis of randomized clinical trials</article-title>
                  <source>Aust Dent J</source>
                  <year>2021</year>
                  <volume>66</volume>
                  <issue>3</issue>
                  <fpage>295</fpage>
                  <lpage>303</lpage>
                  <pub-id pub-id-type="doi">10.1111/adj.12835</pub-id>
                  <?supplied-pmid 33682925?>
                  <pub-id pub-id-type="pmid">33682925</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yuan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Qiu</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Ye</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Hou</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Liang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Jiang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy of topical administration for oral lichen planus: a network meta-analysis</article-title>
                  <source>Oral Dis</source>
                  <year>2022</year>
                  <volume>28</volume>
                  <issue>3</issue>
                  <fpage>670</fpage>
                  <lpage>681</lpage>
                  <pub-id pub-id-type="doi">10.1111/odi.13790</pub-id>
                  <?supplied-pmid 33529456?>
                  <pub-id pub-id-type="pmid">33529456</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scully</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Eisen</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Carrozzo</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Management of oral lichen planus</article-title>
                  <source>Am J Clin Dermatol</source>
                  <year>2000</year>
                  <volume>1</volume>
                  <issue>5</issue>
                  <fpage>287</fpage>
                  <lpage>306</lpage>
                  <pub-id pub-id-type="doi">10.2165/00128071-200001050-00004</pub-id>
                  <?supplied-pmid 11702320?>
                  <pub-id pub-id-type="pmid">11702320</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Åukaszewska-Kuska</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ålebioda</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Dorocka-Bobkowska</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>The effectiveness of topical forms of dexamethasone in the treatment of oral lichen planus- a systematic review</article-title>
                  <source>Oral Dis</source>
                  <year>2021</year>
                  <volume>28</volume>
                  <issue>8</issue>
                  <fpage>2063</fpage>
                  <lpage>2071</lpage>
                  <pub-id pub-id-type="doi">10.1111/odi.13966</pub-id>
                  <?supplied-pmid 34273228?>
                  <pub-id pub-id-type="pmid">34273228</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lodi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Tarozzi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sardella</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Demarosi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Canegallo</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Di Benedetto</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Carrassi</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial</article-title>
                  <source>Br J Dermatol</source>
                  <year>2007</year>
                  <volume>156</volume>
                  <issue>6</issue>
                  <fpage>1336</fpage>
                  <lpage>1341</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2133.2007.07883.x</pub-id>
                  <?supplied-pmid 17535232?>
                  <pub-id pub-id-type="pmid">17535232</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brazzini</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Pimpinelli</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use</article-title>
                  <source>Am J Clin Dermatol</source>
                  <year>2002</year>
                  <volume>3</volume>
                  <issue>1</issue>
                  <fpage>47</fpage>
                  <lpage>58</lpage>
                  <pub-id pub-id-type="doi">10.2165/00128071-200203010-00005</pub-id>
                  <?supplied-pmid 11817968?>
                  <pub-id pub-id-type="pmid">11817968</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Xie</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ge</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of intralesional betamethasone for erosive oral lichen planus and evaluation of recurrence: a randomized, controlled trial</article-title>
                  <source>Oral Surg Oral Med Oral Pathol Oral Radiol</source>
                  <year>2013</year>
                  <volume>116</volume>
                  <issue>5</issue>
                  <fpage>584</fpage>
                  <lpage>590</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.oooo.2013.07.023</pub-id>
                  <?supplied-pmid 24119523?>
                  <pub-id pub-id-type="pmid">24119523</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van der Meij</surname>
                      <given-names>EH</given-names>
                    </name>
                    <name>
                      <surname>van der Waal</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications</article-title>
                  <source>J Oral Pathol Med</source>
                  <year>2003</year>
                  <volume>32</volume>
                  <issue>9</issue>
                  <fpage>507</fpage>
                  <lpage>512</lpage>
                  <pub-id pub-id-type="doi">10.1034/j.1600-0714.2003.00125.x</pub-id>
                  <?supplied-pmid 12969224?>
                  <pub-id pub-id-type="pmid">12969224</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thongprasom</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Luangjarmekorn</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Sererat</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Taweesap</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus</article-title>
                  <source>J Oral Pathol Med</source>
                  <year>1992</year>
                  <volume>21</volume>
                  <issue>10</issue>
                  <fpage>456</fpage>
                  <lpage>458</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1600-0714.1992.tb00974.x</pub-id>
                  <?supplied-pmid 1460584?>
                  <pub-id pub-id-type="pmid">1460584</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gobbo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rupel</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Zoi</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Perinetti</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ottaviani</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Di Lenarda</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bevilacqua</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Woo</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Biasotto</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Scoring systems for Oral Lichen Planus used by differently experienced raters</article-title>
                  <source>Med Oral Patol Oral Cir Bucal</source>
                  <year>2017</year>
                  <volume>22</volume>
                  <issue>5</issue>
                  <fpage>e562</fpage>
                  <lpage>e571</lpage>
                  <?supplied-pmid 28809373?>
                  <pub-id pub-id-type="pmid">28809373</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Zeng</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Xiong</surname>
                      <given-names>C-r</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>H-m</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus</article-title>
                  <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
                  <year>2010</year>
                  <volume>110</volume>
                  <issue>2</issue>
                  <fpage>188</fpage>
                  <lpage>195</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.tripleo.2010.03.034</pub-id>
                  <?supplied-pmid 20659697?>
                  <pub-id pub-id-type="pmid">20659697</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xiong</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Meng</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Zeng</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial</article-title>
                  <source>J Oral Pathol Med</source>
                  <year>2009</year>
                  <volume>38</volume>
                  <issue>7</issue>
                  <fpage>551</fpage>
                  <lpage>558</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1600-0714.2009.00796.x</pub-id>
                  <?supplied-pmid 19486267?>
                  <pub-id pub-id-type="pmid">19486267</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Williamson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hoggart</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Pain: a review of three commonly used pain rating scales</article-title>
                  <source>J Clin Nurs</source>
                  <year>2005</year>
                  <volume>14</volume>
                  <issue>7</issue>
                  <fpage>798</fpage>
                  <lpage>804</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2702.2005.01121.x</pub-id>
                  <?supplied-pmid 16000093?>
                  <pub-id pub-id-type="pmid">16000093</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Behr</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Prasse</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kreuter</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Johow</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rabe</surname>
                      <given-names>KF</given-names>
                    </name>
                    <name>
                      <surname>Bonella</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Bonnet</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Grohe</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Held</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wilkens</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial</article-title>
                  <source>Lancet Respir Med</source>
                  <year>2021</year>
                  <volume>9</volume>
                  <issue>5</issue>
                  <fpage>476</fpage>
                  <lpage>486</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30554-3</pub-id>
                  <?supplied-pmid 33798455?>
                  <pub-id pub-id-type="pmid">33798455</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sandhu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Klein</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Al-Hadlaq</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chirravur</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bajonaid</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Intini</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hussein</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Vacharotayangul</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sroussi</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Oral lichen planus: comparative efficacy and treatment costs-a systematic review</article-title>
                  <source>BMC Oral Health</source>
                  <year>2022</year>
                  <volume>22</volume>
                  <issue>1</issue>
                  <fpage>161</fpage>
                  <pub-id pub-id-type="doi">10.1186/s12903-022-02168-4</pub-id>
                  <?supplied-pmid 35524296?>
                  <pub-id pub-id-type="pmid">35524296</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>De Lucena</surname>
                      <given-names>DD</given-names>
                    </name>
                    <name>
                      <surname>Rangel</surname>
                      <given-names>ÃB</given-names>
                    </name>
                  </person-group>
                  <article-title>Glucocorticoids use in kidney transplant setting</article-title>
                  <source>Expert Opin Drug Metab Toxicol</source>
                  <year>2018</year>
                  <volume>14</volume>
                  <issue>10</issue>
                  <fpage>1023</fpage>
                  <lpage>1041</lpage>
                  <pub-id pub-id-type="doi">10.1080/17425255.2018.1530214</pub-id>
                  <?supplied-pmid 30265586?>
                  <pub-id pub-id-type="pmid">30265586</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parente</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids</article-title>
                  <source>BMC Pharmacol Toxicol</source>
                  <year>2017</year>
                  <volume>18</volume>
                  <issue>1</issue>
                  <fpage>1</fpage>
                  <pub-id pub-id-type="doi">10.1186/s40360-016-0111-8</pub-id>
                  <?supplied-pmid 28057083?>
                  <pub-id pub-id-type="pmid">28057083</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jajarm</surname>
                      <given-names>HH</given-names>
                    </name>
                    <name>
                      <surname>Falaki</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Sanatkhani</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ahmadzadeh</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ahrari</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Shafaee</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>A comparative study of toluidine blue-mediated photodynamic therapy versus topical corticosteroids in the treatment of erosive-atrophic oral lichen planus: a randomized clinical controlled trial</article-title>
                  <source>Lasers Med Sci</source>
                  <year>2015</year>
                  <volume>30</volume>
                  <issue>5</issue>
                  <fpage>1475</fpage>
                  <lpage>1480</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10103-014-1694-1</pub-id>
                  <?supplied-pmid 25487185?>
                  <pub-id pub-id-type="pmid">25487185</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Georgaki</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Piperi</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Theofilou</surname>
                      <given-names>VI</given-names>
                    </name>
                    <name>
                      <surname>Pettas</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Stoufi</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Nikitakis</surname>
                      <given-names>NG</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus</article-title>
                  <source>Med Oral Patol Oral Cir Bucal</source>
                  <year>2022</year>
                  <volume>27</volume>
                  <issue>2</issue>
                  <fpage>e113</fpage>
                  <lpage>e124</lpage>
                  <pub-id pub-id-type="doi">10.4317/medoral.25040</pub-id>
                  <?supplied-pmid 34564686?>
                  <pub-id pub-id-type="pmid">34564686</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ference</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Last</surname>
                      <given-names>AR</given-names>
                    </name>
                  </person-group>
                  <article-title>Choosing topical corticosteroids</article-title>
                  <source>Am Fam Physician</source>
                  <year>2009</year>
                  <volume>79</volume>
                  <issue>2</issue>
                  <fpage>135</fpage>
                  <lpage>140</lpage>
                  <?supplied-pmid 19178066?>
                  <pub-id pub-id-type="pmid">19178066</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>World Health Organization</collab>
                  </person-group>
                  <source>WHO model prescribing information: drugs used in skin diseases</source>
                  <year>1997</year>
                  <publisher-loc>Geneva</publisher-loc>
                  <publisher-name>World Health Organization</publisher-name>
                  <fpage>117</fpage>
                  <lpage>118</lpage>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kopylov</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Novikov</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Kaysheva</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Vykhodets</surname>
                      <given-names>IT</given-names>
                    </name>
                    <name>
                      <surname>Karateev</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Zgoda</surname>
                      <given-names>VG</given-names>
                    </name>
                    <name>
                      <surname>Lisitsa</surname>
                      <given-names>AV</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study</article-title>
                  <source>J Pharm Biomed Anal</source>
                  <year>2018</year>
                  <volume>149</volume>
                  <fpage>278</fpage>
                  <lpage>289</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jpba.2017.11.021</pub-id>
                  <?supplied-pmid 29128828?>
                  <pub-id pub-id-type="pmid">29128828</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>De Porras-Carrique</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>GonzÃ¡lez-Moles</surname>
                      <given-names>MÃ</given-names>
                    </name>
                    <name>
                      <surname>Warnakulasuriya</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ramos-GarcÃ­a</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Depression, anxiety, and stress in oral lichen planus: a systematic review and meta-analysis</article-title>
                  <source>Clin Oral Investig</source>
                  <year>2022</year>
                  <volume>26</volume>
                  <issue>2</issue>
                  <fpage>1391</fpage>
                  <lpage>1408</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00784-021-04114-0</pub-id>
                  <?supplied-pmid 34460001?>
                  <pub-id pub-id-type="pmid">34460001</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hsu</surname>
                      <given-names>D-Y</given-names>
                    </name>
                    <name>
                      <surname>Chien</surname>
                      <given-names>W-C</given-names>
                    </name>
                    <name>
                      <surname>Chung</surname>
                      <given-names>C-H</given-names>
                    </name>
                    <name>
                      <surname>Chiu</surname>
                      <given-names>K-C</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>T-I</given-names>
                    </name>
                    <name>
                      <surname>Kung</surname>
                      <given-names>L-Y</given-names>
                    </name>
                    <name>
                      <surname>Tzeng</surname>
                      <given-names>N-S</given-names>
                    </name>
                  </person-group>
                  <article-title>Risk of anxiety and depression in patients with lichen planus: a nationwide population-based study</article-title>
                  <source>J Affect Disord</source>
                  <year>2022</year>
                  <volume>300</volume>
                  <fpage>255</fpage>
                  <lpage>262</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jad.2021.12.127</pub-id>
                  <?supplied-pmid 34990623?>
                  <pub-id pub-id-type="pmid">34990623</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hou</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Baldwin</surname>
                      <given-names>DS</given-names>
                    </name>
                  </person-group>
                  <article-title>A neuroimmunological perspective on anxiety disorders</article-title>
                  <source>Hum Psychopharmacol</source>
                  <year>2012</year>
                  <volume>27</volume>
                  <issue>1</issue>
                  <fpage>6</fpage>
                  <lpage>14</lpage>
                  <pub-id pub-id-type="doi">10.1002/hup.1259</pub-id>
                  <?supplied-pmid 22213434?>
                  <pub-id pub-id-type="pmid">22213434</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tausk</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Elenkov</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Moynihan</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Psychoneuroimmunology</article-title>
                  <source>Dermatol Ther</source>
                  <year>2008</year>
                  <volume>21</volume>
                  <issue>1</issue>
                  <fpage>22</fpage>
                  <lpage>31</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1529-8019.2008.00166.x</pub-id>
                  <?supplied-pmid 18318882?>
                  <pub-id pub-id-type="pmid">18318882</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Di Giosia</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Stamerra</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Giorgini</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Jamialahamdi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Butler</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Sahebkar</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of nutrition in inflammaging</article-title>
                  <source>Ageing Res Rev</source>
                  <year>2022</year>
                  <volume>77</volume>
                  <fpage>101596</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.arr.2022.101596</pub-id>
                  <?supplied-pmid 35219904?>
                  <pub-id pub-id-type="pmid">35219904</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ezzatt</surname>
                      <given-names>OM</given-names>
                    </name>
                    <name>
                      <surname>Helmy</surname>
                      <given-names>IM</given-names>
                    </name>
                  </person-group>
                  <article-title>Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial</article-title>
                  <source>Clin Oral Investig</source>
                  <year>2019</year>
                  <volume>23</volume>
                  <issue>2</issue>
                  <fpage>947</fpage>
                  <lpage>956</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00784-018-2519-6</pub-id>
                  <?supplied-pmid 29909565?>
                  <pub-id pub-id-type="pmid">29909565</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tyldesley</surname>
                      <given-names>WR</given-names>
                    </name>
                    <name>
                      <surname>Harding</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Betamethasone valerate aerosol in the treatment of oral lichen planus</article-title>
                  <source>Br J Dermatol</source>
                  <year>1977</year>
                  <volume>96</volume>
                  <issue>6</issue>
                  <fpage>659</fpage>
                  <lpage>662</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2133.1977.tb05211.x</pub-id>
                  <?supplied-pmid 326295?>
                  <pub-id pub-id-type="pmid">326295</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alrashdan</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Cirillo</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>McCullough</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Oral lichen planus: a literature review and update</article-title>
                  <source>Arch Dermatol Res</source>
                  <year>2016</year>
                  <volume>308</volume>
                  <issue>8</issue>
                  <fpage>539</fpage>
                  <lpage>551</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00403-016-1667-2</pub-id>
                  <?supplied-pmid 27349424?>
                  <pub-id pub-id-type="pmid">27349424</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <mixed-citation publication-type="other">Wu Y, Xu H, Wang Y, Li C, Tang G, Hua H, Li X, Jin X, Zeng X, Zhou Y et al (2022) An improved scoring system for monitoring oral lichen planus: a preliminary clinical study. Oral Dis. 10.1111/odi.14273</mixed-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ormond</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>McParland</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Thakrar</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Donaldson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Andiappan</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Escudier</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Higham</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hullah</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>McMillan</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Validation of an Oral Disease Severity Score for use in oral lichen planus</article-title>
                  <source>Br J Dermatol</source>
                  <year>2022</year>
                  <volume>186</volume>
                  <issue>6</issue>
                  <fpage>1045</fpage>
                  <lpage>1047</lpage>
                  <pub-id pub-id-type="doi">10.1111/bjd.20968</pub-id>
                  <?supplied-pmid 34984665?>
                  <pub-id pub-id-type="pmid">34984665</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zeng</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Refractory oral lichen planus: a definition employing statistical analysis</article-title>
                  <source>Oral Dis</source>
                  <year>2022</year>
                  <volume>28</volume>
                  <issue>8</issue>
                  <fpage>2172</fpage>
                  <lpage>2174</lpage>
                  <pub-id pub-id-type="doi">10.1111/odi.14124</pub-id>
                  <?supplied-pmid 34990048?>
                  <pub-id pub-id-type="pmid">34990048</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
